logo-loader
CytoDyn

CytoDyn brings on senior science advisor to develop leronlimab to treat HIV PrEP

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive Investors the late stage biotechnology company is tapping industry veteran Dr Jonah Sacha as the company’s senior science advisor.

Dr Pourhassan says Dr Sacha, who has not been given an equity stake in the company, will lead the development of the company’s flagship leronlimab (PRO 140) drug as a potential therapy for HIV pre-exposure prophylaxis (PrEP) and cure for HIV.

Quick facts: CytoDyn

Price: 0.315 USD

Market: OTCMKTS
Market Cap: $122.3 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech's HIV monotherapy dose escalating trial with its flagship drug leronlimab (PRO 140) topped expectations. Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate. 

on 14/8/19

2 min read